Aptar Requests U.S. FDA Emergency Use Authorization for N95 Filtering Facepiece Respirator Decontamination with ActivShield™.

Webinar

Overcoming the challenges in developing an in vitro dissolution and release system for orally inhaled drug products

Read description

Since the local drug concentrations throughout the respiratory tract cannot be measured directly, determining local bioequivalence between two products is more complicated than for systemically acting drugs. Bioavailability of the pulmonary deposited dose, both locally and systemically, is directly affected by the dissolution characteristics at the air- liquid interface. All attempts to understand dissolution differences between products have failed due to limitation in current in vitro dissolution methods.

This webinar will help showcase the utility of the Nanopharm UniDose and In-Vitro Release System (UniDose-IVRT) to investigate the relationship between in vitro dissolution and release characteristics of an aerosol dose. Moreover, we will discuss how our UniDose-Raman system enables analysis of the microstructure of the aerosol dose and correlation to the dissolution characteristics of the drug substance.

This Webinar allows an opportunity for scientists, regulatory aspects and senior managers an opportunity to learn about novel advanced analytical approaches for the characterisation of orally inhaled drug products. This webinar is applicable to those working in formulation R&D, new drug products and generic drug products. We welcome you all to an exciting and informative webinar presented by world renowned innovator in respiratory drug product development Professor Robert Price.

Presented by

Professor Rob Price Chief Scientific Officer, Nanopharm UK and Professor of Pharmaceutics at Bath University, UK
Prof. Rob Price is an acknowledged leader in the field of OINDPs. Rob is the Chief Scientific Officer of Nanopharm Ltd, which is a company he founded specialising in the development of orally inhaled and nasal drug products. His research has been interfaced between engineering, pharmaceutical technology and computational pharmaceutics. He has patented several technologies and out licenced many of his inventions. Rob is a KOL in the orally inhaled and nasal drug product area and has been the recipient of several grants and contracts from the FDA’s Office of Generics. https://uk.linkedin.com/in/profrobertprice
Please register to view the webinar :Already registered ?
Mandatory fields

*The information marked with (*) is essential to process your request. Failure to provide such information may prevent us from fulfilling your request. Your personal data will be used only for Aptar to process an information request and/or job application and will be made accessible to Aptar and to any third party for exclusively technical and logistical reasons, notably to our services located outside the European Union, being specified that, in the event that the recipient country does not ensure a level of data protection equivalent to that of the European Union, Aptar undertakes to take all relevant guarantees, either on the basis of an adequacy decision or, in the absence of such a decision, on the basis of appropriate safeguards, a copy of which may be requested from the contact email below. Your personal data will only be kept for a period that does not exceed the applicable statutory limitation periods. Any contact data will be made accessible to Aptar and to third parties that provide technical and logistical support to Aptar for the purpose of your contact request.

If any after communication upon receipt of a valid identity document, you have the right to access, modify, rectify, limit, delete and ask, if any, the portability of your personal data as well as a right of opposition, if necessary subject to legitimate and imperative reasons, to the processing of such data. You may also define guidelines for the use of your personal data in the event of death.

If you wish to exercise this option or if you have any questions regarding our General Terms and Conditions of Use, Privacy and Cookies Policy, please contact Aptar at: informationgovernance@aptar.com

You also have the right to lodge a complaint at the relevant data protection authority in your own jurisdiction.

April 21, 2020 3PM London / 10AM New York 60 min
Watch now
Presented by
Professor Rob Price Chief Scientific Officer, Nanopharm UK and Professor of Pharmaceutics at Bath University, UK
Read more
Key Learning Objectives
  • To learn about the range of dissolution tests available for orally inhaled drug products
  • The importance of dissolution testing and release characteristics for orally inhaled drug products
  • How to accelerate and de risk the development of orally inhaled and nasal drug product development
Do you have questions about this webinar ?
Contact us